Blood experiment to predict kidney disease

A study has exposed that measuring three biomarkers in a single blood sample might improve physicians' ability to recognize patients at high risk of developing chronic kidney disease (CKD). "Our results recognize biomarkers that can develop CKD risk prediction," comments Caroline S. Fox, MPH of the National Heart, Lung, and Blood Institute's Framingham Heart Study, Framingham, Mass. The study included more than 2,300 participants in the Framingham Offspring Study, a long term follow-up study of heart disease risk factor and outcomes. All participants had usual kidney function when they provide blood samples in 1995-98. An average of 9.5 years later, nine percent of patients had expanded CKD.

Another eight percent had tall levels of protein in the urine at follow-up a key sign of deteriorating kidney function Stored blood samples from 1995-98 were experienced to see if any of six different biomarkers could predict which patients were most likely to expand CKD. A mixture of three biomarkers significantly improved the ability to recognize patients at high risk of CKD, including homocysteine, a marker of atherosclerosis risk, and aldosterone, a hormone that affect salt handling by the kidneys. The same two biomarkers also predict the risk of macroalbuminuria, as did B-type natriuretic peptide (BNP) an indicator of heart damage in patients with heart failure.

useful links : transport rankings